Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma

Table 1 Summary of studies comparing the impact of anti-viral treatment vs no treatment in hepatocellular carcinoma recurrence

Ref.	Antiviral	Treated with antiviral		Untreated		OR (95%CI)
		Total	Events	Total	Events
Wu et al[41]	Nucleoside analogue	518	106	4051	1765	0.67 (0.55-0.81)
Li et al[33]	Lamivudine	43	33	36	33	0.30 (0.08-1.19)
Koda et al[30]	Nucleoside analogue	22	17	14	12	0.57 (0.09-3.42)
Chuma et al[34]	Lamivudine, adefovir dipivoxil or entecavir	20	8	64	22	2.57 (1.34-4.94)
Hung et al[31]	Lamivudine	10	0	62	30	0.05 (0.00-0.90)
Kuzuya et al[35]	Lamivudine	16	7	33	15	0.93 (0.28-3.11)
Kubo et al[36]	Lamivudine	14	2	10	5	0.17 (0.02-1.16)
Shuqun et al[38]	Lamivudine and thymosin alpha1	16	14	17	17	0.17 (0.01-3.73)
Piao et al[37]	Lamivudine	30	14	40	26	0.47 (0.18-1.19)